Know Cancer

forgot password

Evaluation of the Effects of Local GM-CSF-in-Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes

18 Years
85 Years
Not Enrolling

Thank you

Trial Information

Evaluation of the Effects of Local GM-CSF-in-Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes

Regimen: Each injection will be administered to patients with clinical stage I or II
melanoma, who have had complete excision of a primary melanoma, but prior to wide excision
with or without sentinel node biopsy as definitive surgical therapy.

In Stage 1: Patients will be injected with a 1 ml emulsion containing GM-CSF in saline plus
Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.

In Stage 2: Patients will be randomized to receive an injection of one of the following in
skin adjacent to the melanoma biopsy scar:

1. 1 ml saline

2. GM-CSF in 1 ml saline

3. an emulsion of Montanide ISA-51 adjuvant and saline

4. an emulsion of GM-CSF in saline plus ml Montanide ISA-51 adjuvant. All vaccines will be
administered intradermally. After the injection, each patient will undergo wide
excision of the melanoma site, with or without sentinel node biopsy, as clinically

Inclusion Criteria:

- Patients who have been diagnosed, by histologic and clinical examination, with
resected AJCC stage I or II melanoma.

- Patients who have any evidence of metastasis will not be eligible.

- All patients must have:

1. Karnofsky performance of 80% or higher

2. ECOG performance status of 0 or 1

3. Ability and willingness to give informed consent

- Laboratory parameters as follows:

1. ANC: 90% of lower limit of normal (LLN) to 120% of upper limit of normal (ULN)

2. Platelets: 100-500 x 103/uL

3. Hgb: 90% LLN to 120% ULN

4. Hepatic:

1. AST, ALT, Bilirubin, and Alk phos within normal limits,

2. LDH up to 1.2 x ULN

5. Renal:

1. Creatinine up to 1.5 x ULN

- Age 18-85 years at the time of study entry.

Exclusion Criteria:

- Patients who are currently receiving cytotoxic chemotherapy, interferon, or radiation
or who have received this therapy within the preceding 12 weeks.

- Patients with known or suspected allergies to any component of the vaccine.

- Patients receiving the following medications at study entry or within the preceding 4
weeks are excluded:

- Agents with putative immunomodulating activity (with the exception of
non-steroidal anti-inflammatory agents),

- Allergy desensitization injections,

- Corticosteroids, administered parenterally or orally. Topical corticosteroids
are acceptable.

- Any growth factors, Interleukin-2 or other interleukins.

- Pregnancy or the possibility of becoming pregnant during vaccine administration.
Female patients of child-bearing potential must have a negative pregnancy test
(urinary or serum beta-HCG) prior to administration of the injection.

- Patients in whom there is a medical contraindication or potential problem in
complying with the requirements of the protocol, in the opinion of the investigator.

- Patients classified according to the New York Heart Association classification as
having Class III or IV heart disease.

- Patients with serious symptomatic active pulmonary disease, with pleural effusions,
or with a history of pulmonary edema.

- Patients who have systemic autoimmune disease with visceral involvement.

- Patients with clinically apparent skin infection or other clinically evident
inflammation involving the skin adjacent to the melanoma biopsy scar.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of dendritic cells (total and mature) accumulating in the dermis after administration of the adjuvant

Safety Issue:


Principal Investigator

Craig L Slingluff, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Virginia


United States: Food and Drug Administration

Study ID:




Start Date:

June 2004

Completion Date:

Related Keywords:

  • Melanoma
  • Melanoma
  • adjuvant
  • dendritic cells
  • vaccine
  • Melanoma



University of Virginia Charlottesville, Virginia  22908